CJC-1295

Overview

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), the endogenous hypothalamic peptide responsible for stimulating pituitary GH secretion. It is a 30-amino-acid peptide modified to resist enzymatic degradation by dipeptidyl peptidase IV (DPP-IV), significantly extending its circulating half-life compared to native GHRH.

The without-DAC (Drug Affinity Complex) formulation of CJC-1295 produces pulsatile GH release that more closely mirrors the physiological pattern of endogenous growth hormone secretion, in contrast to the prolonged GH bleed associated with DAC-conjugated variants. This characteristic makes it a frequently studied compound in GH axis modulation research.

Research Highlights

Animal and early human studies have documented CJC-1295's ability to produce sustained elevations in plasma GH and IGF-1 concentrations following administration. Research in this area explores correlations between GH axis stimulation and outcomes including lean muscle mass accretion, adipose tissue reduction, improved recovery metrics, enhanced sleep architecture, and immune function modulation.

CJC-1295 is frequently studied in combination with ghrelin-mimetic peptides such as ipamorelin, as the two peptides engage complementary receptor pathways in GH secretion, potentially producing synergistic effects on GH pulse amplitude without proportional increases in cortisol or prolactin — a distinction commonly highlighted in selectivity-focused research.

For research use only. Not intended for human consumption.

Specifications

Certificate of Analysis

Each batch is independently tested by a third-party laboratory. A Certificate of Analysis (COA) confirming purity and identity is available upon request. Contact us with your order number to receive the COA for your specific lot.